Aimed Alliance Comments on IRA Patient Listening Sessions
Recently, Aimed Alliance submitted a comment to the Centers for Medicaid and Medicare Services (CMS) on the Patient Listening Sessions…
Browsing: Drug Pricing
New Report Highlights Value of Treatments to Patients
A recent report by the Alliance for Patient Access (AfPA) titled “At What Price? Medication Value, Patient Care & the…
GOA Finds Rebates Do Not Lower Consumer Costs
A recent report by the Government Accountability Office found that despite the substantial rebates private plans received for Medicare Part…
MDPC sends letter to MA Legislature on Use of QALYs
On September 19, 2023, the Movement Disorders Policy Coalition (MDPC) sent a letter to Chairwoman Friedman and Chairman Lawn of…
Aimed Alliance Comments on CMS’s 340B Proposed Rule
On September 11, 2023, Aimed Alliance sent a letter to Centers for Medicare and Medicaid Services (CMS) commenting on CMS’s…
Report Suggests Fair Access Criteria as Effective Tool to Encourage Increased Drug Access
On January 17, 2023, the Institute for Clinical and Economic Review (ICER) published its second annual “Barriers to Fair Access”…
Aimed Alliance Comments on Build Back Better and Future Healthcare Reform
On November 26, 2021, Aimed Alliance sent a letter to U.S. Senators Carper, Coons, Cortez, Masto, Menendez, Murray, Sinema, Schumer and Wyden…
Aimed Alliance Submits Comment on Most Favored Nation Rule Revocation
On October 12, 2021, Aimed Alliance submitted a comment to the Centers for Medicare & Medicaid Services (CMS) on its proposed rule…
Congress Can Lower Drug Prices by Following West Virginia’s Lead in Passing Rebates to Consumer
A new op-ed by Dr. Chris Stansbury details a potential new approach for Congress in controlling prescription drug prices: regulating…
Aimed Alliance Releases New Fact Sheet on H.R. 3, Detailing Pros and Cons to Patient Welfare
Aimed Alliance has created a new fact sheet dedicated to H.R. 3, otherwise known as the Elijah E. Cummings Lower…